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Dipeptidyl peptidase-4 (DPP-4) inhibitors reduce the risk of hypoglycaemia, possibly through
augmentation of glucose-dependent insulinotropic polypeptide (GIP) action, but not that of
glucagon-like peptide-1 (GLP-1) on glucagon secretion. To examine this model in Japanese indi-
viduals with type 2 diabetes (T2D), the effects of the DPP-4 inhibitor linagliptin on glucagon
and other counter-regulatory hormone responses to hypoglycaemia were evaluated and
compared with those of the GLP-1 receptor agonist liraglutide in a multi-centre, randomized,
open-label, 2-arm parallel comparative, exploratory trial. Three-step hypoglycaemic clamp
glucose tests preceded by meal tolerance tests were performed before and after 2-week treat-
ment with the drugs. Glucagon levels were increased during the hypoglycaemic clamp test at
2.5 mmol/L. This increase was similar in the linagliptin and liraglutide groups, both before and
after the 2-week treatment. Changes in other counter-regulatory hormones (ie, growth
hormone, cortisol, epinephrine and norepinephrine) were also similar between the groups, but
were suppressed substantially after 2-week treatment compared to baseline. In conclusion, we
confirmed that the glucagon response to hypoglycaemia was not affected by linagliptin or
liraglutide treatment in Japanese individuals with T2D.
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1 | INTRODUCTION
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used in treat-
ment of type 2 diabetes (T2D).1,2 DPP-4 inhibitors increase biologi-
cally intact forms of glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1), both of which enhance
glucose-induced insulin secretion from pancreatic β-cells.3,4 GLP-1
suppresses glucagon secretion from pancreatic α-cells when glucose
levels are high,5,6 whereas GIP augments glucagon secretion in
response to hypoglycaemia.7–10 Thus, enhancement of GIP and
GLP-1 actions by DPP-4 inhibitors should contribute, not only to
amelioration of hyperglycaemia, but also to mitigation of severe
hypoglycaemia. It was reported that the DPP-4 inhibitor vildagliptin
enhances the glucagon response to hypoglycaemia in drug-naïve indi-
viduals with T2D,11 whereas the glucagon response to hypoglycaemia
was not affected by GLP-1 receptor (GLP-1R) agonists.12,13 This
might suggest differing effects of DPP-4 inhibitors and GLP-1R ago-
nists on the glucagon response to hypoglycaemia, which needs to be
examined in head-to-head studies. In this study, we compared effects
of the DPP-4 inhibitor linagliptin with those of the GLP-1R agonist
liraglutide on the responses to hypoglycaemia of glucagon and other
counter-regulatory hormones in Japanese individuals with T2D.
2 | METHODS
2.1 | Study protocol
This was a multi-centre, randomized, prospective, open-label, 2-arm
parallel comparative, exploratory study in Japanese individuals with
T2D (UMIN-CTR clinical trial registration number: UMIN000014417).
Those eligible were randomized in a 1-to-1 ratio to a linagliptin or lira-
glutide treatment group by computer-based dynamic allocation, taking
gender, age and BMI into consideration for stratified randomization
based on screening results at visit 1 (V1, week −4). A meal tolerance
test (MTT) and stepped hyperinsulinaemic glucose clamp test (SHGCT)
were performed at visit 2 (V2, day 0) and visit 3 (V3, day 14); blood
samples were obtained and analysed as described in File S1. Subjects
received study medication for 14 days (days 1-14), linagliptin 5 mg
once daily or liraglutide 0.3 mg via subcutaneous injection once daily
from day 1 to day 6 and 0.6 mg from day 7 to day 14. Liraglutide up
to only 0.9 mg once daily is the dosage approved in Japan. Subjects
were recruited and screened in 2 medical institutions in Osaka and
Fukuoka, Japan after obtaining approval of the respective ethics com-
mittees. Randomization was performed at A2 Healthcare Corp in
Tokyo, Japan. Data were collected in an inpatient ward of the medical
institution in Fukuoka, Japan. Recruitment of subjects began July
5, 2014 and the last follow-up date was April 20, 2015. Written
informed consent was obtained from all subjects.
2.2 | Study population
Eligible Japanese individuals with T2D were age 40-70 years with a
body mass index (BMI) < 30 kg/m2, and a treatment history of a single
oral hypoglycaemic agent with HbA1c 6.0% to 8.0% (42-64 mmol/
mol) or no drug treatment with HbA1c 6.0% to 8.5% (42-69 mmol/
mol). Individuals requiring insulin therapy, or those treated with insu-
lin, DPP-4 inhibitors or GLP-1 receptor agonists during the 4 weeks
before informed consent, or those treated with pioglitazone during
the 12 weeks before informed consent were excluded, as were those
with cardiac failure or history of cerebro-cardiovascular disease or
pancreatitis. The sample size was not based on a power calculation as
this was an exploratory pilot study; however, the sample size would
seem to be appropriate in the context of previous, related studies.9,11
2.3 | Study assessments
Major outcomes were changes in glucagon and other counter-
regulatory hormones (ie, epinephrine, norepinephrine, cortisol and
growth hormone [GH]) during SHGCT following 2-week treatment
with linagliptin or liraglutide in the per protocol set (PPS) population
(ie, subjects who received 14-day administration of study medication
with successful completion of SHGCT on both V2 and V3). All adverse
events (AE) were collected and AE by system organ class/preferred
terms, serious adverse events (SAE) and discontinuation from AE were
summarized for the full analysis set (FAS) population (ie, subjects who
received at least 1 dose of study medication, with data from at least
1 point of safety available after drug administration, regardless of suc-
cessful completion of SHGCT on either V2 or V3).
2.4 | Statistical analysis
All analyses were performed using SAS version 9.4 (SAS Institute,
Inc., Cary, North Carolina). Results are reported as mean  SE unless
otherwise stated. Area-under-the curve (AUC) of each measurement
was calculated according to the trapezoidal rule. Repeated measures
were analysed with mixed-design analysis of covariance (ANCOVA).
The changes of each measurement from 225 to 255 minutes were
tested using two sample t test. A 2-sided P value < .05 was taken to
indicate significant difference.
3 | RESULTS
Thirty-five screened subjects were randomized to the linagliptin
treatment group or the liraglutide treatment group; they received
study assessments at V2 and V3 and were analysed as the FAS popu-
lation (Table 1 and Figure S1). Six of them did not reach the target
blood glucose level in the hypoglycaemic phase at V2 and/or V3 and
were excluded from the PPS population.
MTT were performed to increase GIP and GLP-1 prior to SHGCT.
Glucose levels were similar between the linagliptin and liraglutide
groups at V2, and were decreased similarly at V3, to a greater degree
in the liraglutide group (Table S1 and Figure S2). C-peptide and ISR
were significantly higher in the liraglutide group at V2 and V3, and
were similarly enhanced at V3 compared to V2 in both groups. Gluca-
gon tended to be higher in the liraglutide group at V2 and V3, but
was similarly suppressed at V3 compared to V2 in both groups. Intact
GIP levels were similar in the two groups at V2, and were increased
at V3 only in the linagliptin group; GIP levels were similar between
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the two groups at V2 and V3 (Table S1 and Figure S3). Total and
intact GLP-1 were not determined in the liraglutide group throughout
the study because of the difficulty in differentiating liraglutide from
endogenous GLP-1.
SHGCT were performed immediately after MTT. Glucose levels at
V2 and V3 in both groups were similarly decreased during euglycaemic
and hypoglycaemic phases (Figure S4). After discontinuation of insulin
infusion at 255 minutes, blood glucose recovered similarly at V2 and
V3 in both groups. The recovery from hypoglycaemia exhibited no sig-
nificant difference between groups and glucose infusion rates (IIR) from
255 to 300 minutes were similar between groups and between visits.
Glucose infusion rates were also similar between groups and between
visits (Figure S7). ISR at V3 was higher than that at V2 during the hyper-
glycaemic and euglycaemic phases, but there was no difference in ISR
during the hypoglycaemic phase between the two groups or between
visits (Table 2 and Figure S4). During the hyperglycaemic and euglycae-
mic phases, glucagon at V2 and V3 were nearly unchanged and were
similar in both groups (Table 2 and Figure S5). Glucagon increased rap-
idly during the hypoglycaemic phase and there was no difference in glu-
cagon response between groups or between visits. Total GIP levels
were similar between groups at V2 and V3. Intact GIP levels were simi-
lar between groups at V2, and were increased only in the linagliptin
group at V3. GH, cortisol, epinephrine and norepinephrine were
increased during the latter half of the hypoglycaemic phase at V2 and
V3 (Table 2 and Figure S6). The changes in GH, cortisol, epinephrine
and norepinephrine at V3 were less than those at V2 in both groups.
The overall results in the FAS population were fully consistent with
those of the PPS population (data not shown).
3.1 | Safety
AE and SAE were analysed in the FAS population. No AE was
reported in the linagliptin group. One subject in the liraglutide group
experienced nausea, which was assessed as non-serious and
treatment-related. No SAE was experienced by any individual in
either group.
4 | DISCUSSION
A main finding of this study comparing linagliptin with liraglutide in
Japanese individuals with T2D confirms our general understanding
that incretin therapies do not prevent hypoglycaemia-induced gluca-
gon secretion, as was previously reported for the DPP-4 inhibitor vil-
dagliptin and the GLP-1R agonists albiglutide and lixisenatide in
individuals with T2D.11–14 This supports the notion that these thera-
pies are not associated with increased risk of hypoglycaemia. Impor-
tantly, the present study shows that linagliptin did not enhance
hypoglycaemia-induced glucagon secretion even though biologically
intact GIP was significantly elevated. It has been shown previously
that vildagliptin enhanced hypoglycaemia-induced glucagon secretion
in drug-naive individuals with T2.11 Discrepancies between that study
and ours could be explained by the following possibilities. First, dif-
ferent DPP-4 inhibitors were used for different treatment periods (ie,
vildagliptin, 4 weeks; linagliptin, 2 weeks). Second, different compari-
sons were made (ie, vildagliptin vs placebo; linagliptin vs liraglutide;
before vs after linagliptin treatment). Third, different ethnic groups
were studied (ie, Caucasian vs Japanese); T2D in East Asians, includ-
ing Japanese, is characterized primarily by β-cell dysfunction with less
adiposity and it differs phenotypically from T2D in Caucasians,15
showing greater HbA1c reduction in response to DPP-4 inhibitors
and GLP-1R agonists.16,17 Finally, subjects with different baseline
HbA1c levels were enrolled (ie, mean HbA1c 6.3% vs 7.3%). It could
therefore be possible that glucagonotropic effects of GIP might be
impaired by chronic hyperglycaemia, similarly to the insulinotropic
effects of GIP.18 Interestingly, enhancement of the hypoglycaemia-
TABLE 1 Demographic and baseline characteristics of full analysis set and per protocol set populations
Full analysis set Per protocol set
Linagliptin Liraglutide P value Linagliptin Liraglutide P value
n (male/female) 18 (13/5) 17 (12/5) 15 (11/4) 14 (10/4)
Age (years) 58.56  7.81 57.76  7.63 .764 59.53  7.12 56.79  7.66 .326
BMI (kg /m2) 23.82  2.29 23.98  3.15 .871 23.47  1.93 23.88  3.49 .702
Waist circumference (cm) 86.79  8.86 87.46  10.85 .842 86.05  9.2 85.53  10.8 .889
Duration (years) 4.00  3.66 3.59  5.73 .801 4.67  3.66 3.50  6.02 .530
FPG (mg/dL) 143.89  31.19 139.65  27.36 .672 146.73  33.54 137.21  28.34 .418
HbA1c (%) 7.38  0.71 7.21  0.59 .441 7.37  0.75 7.14  0.57 .375
OAD use (%) 0 0 0 0
Systolic BP (mm Hg) 130.44  10.99 128.24  9.26 .526 131.40  11.56 127.93  8.91 .376
Diastolic BP (mm Hg) 78.89  6.91 78.47  8.24 .871 78.67  7.47 78.43  9.10 .939
Total-cholesterol (mg/dL) 217.28  38.44 224.76  45.15 .600 219.13  36.38 217.29  44.89 .904
HDL-cholesterol (mg/dL) 59.17  16.19 61.41  15.74 .680 61.53  16.08 63.21  16.78 .785
Triglyceride (mg/dL) 157.39  96.03 120.65  34.94 .143 148.20  99.38 112.79  32.47 .208
DPP-4 activity (nmol/mL/min) 8.73  1.66 9.02  1.95 .639 8.76  1.72 9.19  2.09 .542
Each value represents mean  standard deviation.
Abbreviations: BMI, body mass index; BP, blood pressure; DPP-4, dipeptidyl peptidase-4; FPG, fasting plasma glucose; HDL, high density lipoprotein;
OAD, oral anti-diabetic drugs.
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induced glucagon response by GIP or vildagliptin was observed in
T2D individuals with mean baseline HbA1c values between 6.3% and
6.5%,7,11 but there was little enhancement by vildagliptin in indivi-
duals with T2D with a mean baseline HbA1c value of 7.7%.14 Further
investigations are required to clarify the discrepancies between these
two studies.
In the current study, the hypoglycaemia-induced responses of
the counter-regulatory hormones GH, cortisol, epinephrine and nor-
epinephrine were attenuated at V3 compared to those at V2, which
is similar to the effect of DPP-4 inhibitor linagliptin and the GLP-1
receptor agonist liraglutide (Table 2 and Figure S6). The lack of pla-
cebo or euglycaemic control groups in our study does not permit
exclusion of the possibility that the subjects’ experiences at V2 might
affect the counter-responses of GH, cortisol, epinephrine and norepi-
nephrine seen at V3. Furthermore, the variable IIR could result in dif-
ferent insulin levels between tests that might affect responses of the
counter-regulatory hormones. However, a recent study in T2D indivi-
duals reported suppressive effects on hypoglycaemia-induced
sympatho-adrenal response after treatment with the GLP-1 receptor
agonist lixisenatide,13 which are similar to our present findings.
Co-administration of some incretin therapies in insulin and/or
sulfonylurea-treated individuals with T2D would seem to have poten-
tial for preventing hypoglycaemia-induced release of cortisol and cat-
echolamine, and thus possibly reduce cardiovascular event risks.
However, further investigations are needed to clarify the underlying
mechanisms and clinical relevance of the current findings, as most
previous studies on incretin therapies did not show similar suppres-
sive effects in individuals with T2D or type 1 diabetes.11,19,20 In con-
clusion, neither the DPP-4 inhibitor linagliptin nor the GLP-1 receptor
agonist liraglutide impaired the alpha-cell responsiveness to hypogly-
caemia in Japanese individuals with T2D.
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